Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.
相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
100.0%
暂无批准数据
- Stoke Therapeutics surged 11.42% after presenting positive data for zorevunersen in Dravet syndrome at the 2025 AES Annual Meeting with partner Biogen. - Alpha Tau Medical climbed 25.26% following announcement that the first patient was treated in its pilot study for recurrent glioblastoma multiforme using Alpha DaRT technology. - Senti Biosciences gained 3.92% after the FDA granted RMAT designation to SENTI-202, an investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies. - Multiple biotech companies showed strong after-hours performance driven by clinical data presentations, regulatory progress, and financing announcements across various therapeutic areas.
- Senti Bio's SENTI-202, a first-in-class Logic Gated CAR-NK cell therapy, demonstrated a 50% overall response rate and 42% complete remission rate in relapsed/refractory acute myeloid leukemia patients at the recommended Phase 2 dose. - The FDA granted SENTI-202 Regenerative Medicine Advanced Therapy (RMAT) designation, marking the second FDA recognition this year following Orphan Drug Designation in June 2025. - Clinical data showed 100% of complete remissions were MRD negative with a median duration of 7.6 months, while pharmacodynamic studies validated the therapy's selective targeting mechanism that kills cancer cells while sparing healthy bone marrow cells. - The therapy demonstrated a favorable safety profile with no dose-limiting toxicities or serious adverse events related to SENTI-202, supporting potential outpatient delivery for this heavily pretreated patient population.
- DelveInsight's analysis reveals a robust acute myeloid leukemia pipeline with over 100 companies actively developing 150+ therapeutic candidates across various clinical stages. - Recent regulatory milestones include FDA approval of KOMZIFTI (ziftomenib) for relapsed/refractory NPM1-mutated AML and priority review acceptance for revumenib, both representing first-in-class menin inhibitors. - The pipeline features diverse therapeutic approaches including targeted therapies like isocitrate dehydrogenase inhibitors, immunotherapies, and novel mechanisms of action addressing unmet medical needs in this aggressive blood cancer.
- Senti Bio will present updated clinical results for SENTI-202, a first-in-class logic gated CAR-NK cell therapy, at the American Society of Hematology Annual Meeting in December 2025. - The therapy demonstrates deep and durable clinical remission rates with a strong safety profile in patients with relapsed/refractory acute myeloid leukemia. - SENTI-202's OR/NOT Logic Gate technology shows selective killing of leukemic blasts and stem cells while sparing healthy hematopoietic stem and progenitor cells. - The company reported $12.2 million in cash and cash equivalents as of September 30, 2025, down from $48.3 million at year-end 2024.
- Senti Bio received an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon achieving clinical enrollment milestones for its SENTI-202 CAR-NK therapy trial. - SENTI-202 demonstrated encouraging preliminary Phase 1 results with 4 of 7 evaluable patients achieving complete remission and no dose-limiting toxicities observed. - The first-in-class Logic Gated CAR-NK therapy targets CD33 and FLT3-expressing blood cancers while sparing healthy bone marrow cells through its innovative design.
- Senti Biosciences presented positive preliminary data from its Phase 1 trial of SENTI-202, showing 5 of 7 evaluable patients with relapsed/refractory AML achieved objective responses, including 4 complete remissions that were all MRD-negative. - SENTI-202, a first-in-class off-the-shelf logic-gated CAR-NK cell therapy targeting CD33 and FLT3 while sparing healthy cells, demonstrated a favorable safety profile with no dose-limiting toxicities and durable responses lasting up to 8+ months. - The company has identified a preliminary recommended Phase 2 dose and will continue enrollment to confirm dosing before advancing to disease-specific expansion cohorts, with additional data presented at the AACR Annual Meeting 2025.
- SENTI-202, a first-in-class CAR NK cell therapy using innovative logic-gating technology, achieved complete remission in four of seven evaluable patients with relapsed/refractory acute myeloid leukemia. - Unlike traditional CAR T-cell therapies, SENTI-202 offers an "off-the-shelf" approach using healthy donor cells that can be quickly administered to patients with rapidly progressing AML, addressing a critical treatment gap. - The therapy's dual-targeting mechanism (CD33 and FLT3) combined with an inhibitory receptor that protects healthy cells demonstrates a promising safety profile with durable responses lasting up to eight months.
- Senti Bio's SENTI-202, a gene circuit-enabled CAR-NK cell therapy, achieved MRD-negative complete remission in 2 of 3 relapsed/refractory AML patients at the lowest dose level in its Phase 1 trial, with both patients maintaining remission. - The company secured approximately $47.6 million through a PIPE financing led by Celadon Partners, extending its financial runway into 2026 and supporting continued development of its gene circuit platform technology. - Senti Bio's proprietary Gene Circuit platform is designed to create cell therapies with enhanced precision and control, potentially offering new treatment options for patients with challenging liquid and solid tumors.
• DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer. • Several promising candidates are advancing through clinical trials, including GlycoMimetics' uproleselan in Phase III, BioSight's aspacytarabine (BST-236) in Phase II, and novel approaches like Senti Biosciences' logic-gated CAR-NK cell therapy. • Recent developments include Moleculin Biotech's Phase III MIRACLE trial for annamycin, Qurient's adrixetinib IND approval, and Rigel Pharmaceuticals' trial of REZLIDHIA in combination therapy for IDH1-mutated AML.
- The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034. - Leading companies including Artiva Biotherapeutics, Glycostem, Fate Therapeutics, and Senti Biosciences are developing promising therapies such as AlloNK, oNKord, and FT522, with several receiving FDA designations for expedited development. - Off-the-shelf NK cell therapies are emerging as a key trend, offering advantages in manufacturing scalability, immediate availability, and potential applications beyond oncology into autoimmune diseases.
